Yumita Nagahiko, Umemura Shin-Ichiro
School of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan.
J Pharm Pharmacol. 2004 Jan;56(1):85-90. doi: 10.1211/0022357022412.
The sonodynamically induced antitumour effect of chloroaluminum phthalocyanine tetrasulfonate (AlPcTS) was evaluated on subcutaneously implanted colon 26 carcinoma. A time of 24 h after the administration of AlPcTS was chosen for the ultrasonic exposure, based on the analysis of the AlPcTS concentrations in the tumour, plasma, skin and muscle. The pharmacokinetic analysis showed much faster clearance of AlPcTS than photofrin II from the body, which can be an advantage in view of their potential adverse effects. At an AlPcTS dose not less than 2.5 mg kg(-1) and at a free-field ultrasonic intensity not less than 3 W cm(-2), the synergistic effect between AlPcTS administration and ultrasonic exposure on the tumour growth inhibition was significant. The ultrasonic intensity showed a relatively sharp threshold for the synergistic antitumour effect, which is typical for an ultrasonic effect mediated by acoustic cavitation. These results suggest that AlPcTS is a potential sonosensitizer for sonodynamic treatment of solid tumours.
研究了四磺基铝酞菁(AlPcTS)的声动力学诱导抗肿瘤作用,以皮下接种的结肠26癌为模型。基于对肿瘤、血浆、皮肤和肌肉中AlPcTS浓度的分析,选择在给予AlPcTS后24小时进行超声照射。药代动力学分析表明,AlPcTS从体内清除的速度比光敏素II快得多,鉴于它们潜在的不良反应,这可能是一个优势。当AlPcTS剂量不低于2.5 mg kg(-1)且自由场超声强度不低于3 W cm(-2)时,AlPcTS给药与超声照射之间对肿瘤生长抑制的协同作用显著。超声强度对协同抗肿瘤作用表现出相对明显的阈值,这是由声空化介导的超声效应的典型特征。这些结果表明,AlPcTS是实体瘤声动力治疗的潜在声敏剂。